|
|
 Previous Article | Table of Contents | Next Article 
Donor leukocyte transfusions for treatment of recurrent chronic myelogenous
leukemia in marrow transplant patients
HJ Kolb, J Mittermuller, C Clemm, E Holler, G Ledderose, G Brehm, M Heim and W Wilmanns
Medizinische Klinik III, Klinikum Grosshadern, Universtat Munchen, Germany.
Three patients with hematologic relapse after bone marrow transplantation
for chronic myelogenous leukemia were treated with interferon alpha and
transfusion of viable donor buffy coat. All had complete hematologic and
cytogenetic remission, which persisted 32 to 91 weeks after treatment. In
two patients graft-versus-host disease developed and was treated by
immunosuppression. These results are an example of adoptive immunotherapy
without cytoreductive chemotherapy or radiotherapy in human chimeras.
Volume 76,
Issue 12,
pp. 2462-2465,
12/15/1990
Copyright © 1990 by The American Society of Hematology
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
L. T. van der Veken, M. Coccoris, E. Swart, J. H. F. Falkenburg, T. N. Schumacher, and M. H. M. Heemskerk
{alpha}{beta} T Cell Receptor Transfer to {gamma}{delta} T Cells Generates Functional Effector Cells without Mixed TCR Dimers In Vivo
J. Immunol.,
January 1, 2009;
182(1):
164 - 170.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H.-J. Kolb
Graft-versus-leukemia effects of transplantation and donor lymphocytes
Blood,
December 1, 2008;
112(12):
4371 - 4383.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Griffioen, H.M. E. van Egmond, H. Barnby-Porritt, M. A.W.G. van der Hoorn, R. S. Hagedoorn, M. G.D. Kester, N. Schwabe, R. Willemze, J.H. F. Falkenburg, and M. H.M. Heemskerk
Genetic engineering of virus-specific T cells with T-cell receptors recognizing minor histocompatibility antigens for clinical application
Haematologica,
October 1, 2008;
93(10):
1535 - 1543.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
I. F. Khouri, P. McLaughlin, R. M. Saliba, C. Hosing, M. Korbling, M. S. Lee, L. J. Medeiros, L. Fayad, F. Samaniego, A. Alousi, et al.
Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab
Blood,
June 15, 2008;
111(12):
5530 - 5536.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Eto, Y. Kamiryo, A. Takeuchi, M. Harano, K. Tatsugami, M. Harada, K. Kiyoshima, M. Hamaguchi, T. Teshima, M. Tsuneyoshi, et al.
Posttransplant Administration of Cyclophosphamide and Donor Lymphocyte Infusion Induces Potent Antitumor Immunity to Solid Tumor
Clin. Cancer Res.,
May 1, 2008;
14(9):
2833 - 2840.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Griffioen, E. D. van der Meijden, E. H. Slager, M. W. Honders, C. E. Rutten, S. A. P. van Luxemburg-Heijs, P. A. von dem Borne, J. J. van Rood, R. Willemze, and J. H. F. Falkenburg
Identification of phosphatidylinositol 4-kinase type II {beta} as HLA class II-restricted target in graft versus leukemia reactivity
PNAS,
March 11, 2008;
105(10):
3837 - 3842.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Conrad, M. Remberger, K. Cederlund, O. Ringden, and L. Barkholt
A comparison between low intensity and reduced intensity conditioning in allogeneic hematopoietic stem cell transplantation for solid tumors
Haematologica,
February 1, 2008;
93(2):
265 - 272.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Sureda, S. Robinson, C. Canals, A. M. Carella, M. A. Boogaerts, D. Caballero, A. E. Hunter, L. Kanz, S. Slavin, J. J. Cornelissen, et al.
Reduced-Intensity Conditioning Compared With Conventional Allogeneic Stem-Cell Transplantation in Relapsed or Refractory Hodgkin's Lymphoma: An Analysis From the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation
J. Clin. Oncol.,
January 20, 2008;
26(3):
455 - 462.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D.-P. Chen, C.-P. Tseng, S.-H. Tsai, T.-L. Wu, P.-Y. Chang, and C.-F. Sun
Systematic Analysis of Stutters to Enhance the Accuracy of Chimerism Testing
Ann. Clin. Lab. Sci.,
January 1, 2008;
38(3):
264 - 272.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Mackinnon
Donor Lymphocyte Infusion after Allogeneic Stem Cell Transplantation
ASCO Educational Book,
January 1, 2008;
2008(1):
334 - 337.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. Yoshida, T. Hirano, G. Son, Y. Iimuro, T. Imado, T. Iwasaki, and J. Fujimoto
Allogeneic bone marrow transplantation for hepatocellular carcinoma: hepatocyte growth factor suppresses graft-vs.-host disease
Am J Physiol Gastrointest Liver Physiol,
December 1, 2007;
293(6):
G1114 - G1123.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Schmid, M. Labopin, A. Nagler, M. Bornhauser, J. Finke, A. Fassas, L. Volin, G. Gurman, J. Maertens, P. Bordigoni, et al.
Donor Lymphocyte Infusion in the Treatment of First Hematological Relapse After Allogeneic Stem-Cell Transplantation in Adults With Acute Myeloid Leukemia: A Retrospective Risk Factors Analysis and Comparison With Other Strategies by the EBMT Acute Leukemia Working Party
J. Clin. Oncol.,
November 1, 2007;
25(31):
4938 - 4945.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Scheich, J. Duyster, C. Peschel, and H. Bernhard
The immunogenicity of Bcr-Abl expressing dendritic cells is dependent on the Bcr-Abl kinase activity and dominated by Bcr-Abl regulated antigens
Blood,
October 1, 2007;
110(7):
2556 - 2560.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. S. Miller, D. J. Weisdorf, L. J. Burns, A. Slungaard, J. E. Wagner, M. R. Verneris, S. Cooley, R. Wangen, S. K. Fautsch, R. Nicklow, et al.
Lymphodepletion followed by donor lymphocyte infusion (DLI) causes significantly more acute graft-versus-host disease than DLI alone
Blood,
October 1, 2007;
110(7):
2761 - 2763.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Ciceri, C. Bonini, S. Marktel, E. Zappone, P. Servida, M. Bernardi, A. Pescarollo, A. Bondanza, J. Peccatori, S. Rossini, et al.
Antitumor effects of HSV-TK engineered donor lymphocytes after allogeneic stem-cell transplantation
Blood,
June 1, 2007;
109(11):
4698 - 4707.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. Durakovic, V. Radojcic, M. Skarica, K. B. Bezak, J. D. Powell, E. J. Fuchs, and L. Luznik
Factors governing the activation of adoptively transferred donor T cells infused after allogeneic bone marrow transplantation in the mouse
Blood,
May 15, 2007;
109(10):
4564 - 4574.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Sinai, R. E. Berg, J. M. Haynie, M. J. Egorin, R. L. Ilaria Jr, and J. Forman
Imatinib Mesylate Inhibits Antigen-Specific Memory CD8 T Cell Responses In Vivo
J. Immunol.,
February 15, 2007;
178(4):
2028 - 2037.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Eto, M. Harano, K. Tatsugami, M. Harada, Y. Kamiryo, K. Kiyoshima, M. Hamaguchi, M. Tsuneyoshi, Y. Yoshikai, and S. Naito
Cyclophosphamide-Using Nonmyeloablative Allogeneic Cell Therapy against Renal Cancer with a Reduced Risk of Graft-versus-Host Disease
Clin. Cancer Res.,
February 1, 2007;
13(3):
1029 - 1035.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. H. Antin
Reduced-Intensity Stem Cell Transplantation: "...whereof a little More than a little is by much too much." King Henry IV, part 1, I, 2
Hematology,
January 1, 2007;
2007(1):
47 - 54.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. C. Yang and R. Childs
Immunotherapy for Renal Cell Cancer
J. Clin. Oncol.,
December 10, 2006;
24(35):
5576 - 5583.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Mackensen, N. Meidenbauer, S. Vogl, M. Laumer, J. Berger, and R. Andreesen
Phase I Study of Adoptive T-Cell Therapy Using Antigen-Specific CD8+ T Cells for the Treatment of Patients With Metastatic Melanoma
J. Clin. Oncol.,
November 1, 2006;
24(31):
5060 - 5069.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Aschan
Allogeneic haematopoietic stem cell transplantation: current status and future outlook
Br. Med. Bull.,
October 5, 2006;
(2006)
ldl005v2.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. L. Porter
RIC for MDS: the glass is half full
Blood,
August 1, 2006;
108(3):
780 - 781.
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. H. Slager, M. W. Honders, E. D. van der Meijden, S. A. P. van Luxemburg-Heijs, F. M. Kloosterboer, M. G. D. Kester, I. Jedema, W. A. E. Marijt, M. R. Schaafsma, R. Willemze, et al.
Identification of the angiogenic endothelial-cell growth factor-1/thymidine phosphorylase as a potential target for immunotherapy of cancer
Blood,
June 15, 2006;
107(12):
4954 - 4960.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. J. Mauro and R. T. Maziarz
Stem Cell Transplantation in Patients With Chronic Myelogenous Leukemia: When Should It Be Used?
Mayo Clin. Proc.,
March 1, 2006;
81(3):
404 - 416.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. F. Apperley
Managing the Patient with Chronic Myeloid Leukemia Through and After Allogeneic Stem Cell Transplantation
Hematology,
January 1, 2006;
2006(1):
226 - 232.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. M. Kloosterboer, S. A. P. van Luxemburg-Heijs, R. A. van Soest, H. M. E. van Egmond, R. Willemze, and J. H. F. Falkenburg
Up-regulated expression in nonhematopoietic tissues of the BCL2A1-derived minor histocompatibility antigens in response to inflammatory cytokines: relevance for allogeneic immunotherapy of leukemia
Blood,
December 1, 2005;
106(12):
3955 - 3957.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Harano, M. Eto, T. Iwai, K. Tatsugami, K. Kiyoshima, Y. Kamiryo, M. Tsuneyoshi, Y. Yoshikai, and S. Naito
Renal Cancer Treatment with Low Levels of Mixed Chimerism Induced by Nonmyeloablative Regimen Using Cyclophosphamide in Mice
Cancer Res.,
November 1, 2005;
65(21):
10032 - 10040.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S.-A. Xue, L. Gao, D. Hart, R. Gillmore, W. Qasim, A. Thrasher, J. Apperley, B. Engels, W. Uckert, E. Morris, et al.
Elimination of human leukemia cells in NOD/SCID mice by WT1-TCR gene-transduced human T cells
Blood,
November 1, 2005;
106(9):
3062 - 3067.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Lotze, F. Schuler, W. H. Kruger, C. Hirt, M. Kirsch, S. Vogelgesang, C. A. Schmidt, and G. Dolken
Combined immunoradiotherapy induces long-term remission of CNS relapse of peripheral, diffuse, large-cell lymphoma after allogeneic stem cell transplantation: Case study
Neuro-oncol,
October 1, 2005;
7(4):
508 - 510.
[Abstract]
[PDF]
|
|
|
|
|
|
|
J. Greiner, L. Li, M. Ringhoffer, T. F. E. Barth, K. Giannopoulos, P. Guillaume, G. Ritter, M. Wiesneth, H. Dohner, and M. Schmitt
Identification and characterization of epitopes of the receptor for hyaluronic acid-mediated motility (RHAMM/CD168) recognized by CD8+ T cells of HLA-A2-positive patients with acute myeloid leukemia
Blood,
August 1, 2005;
106(3):
938 - 945.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. J. Wu, M. Biernacki, J. L. Kutok, S. Rogers, L. Chen, X.-F. Yang, R. J. Soiffer, and J. Ritz
Graft-versus-Leukemia Target Antigens in Chronic Myelogenous Leukemia Are Expressed on Myeloid Progenitor Cells
Clin. Cancer Res.,
June 15, 2005;
11(12):
4504 - 4511.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. W. N. Deininger
Adoptive immunotherapy of murine CML: navigating between Scylla and Charybdis
Blood,
December 15, 2004;
104(13):
3843 - 3843.
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. S. Krause and R. A. Van Etten
Adoptive immunotherapy of BCR-ABL-induced chronic myeloid leukemia-like myeloproliferative disease in a murine model
Blood,
December 15, 2004;
104(13):
4236 - 4244.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. Takahashi and R. W. Childs
Nonmyeloablative Transplantation: An Allogeneic-Based Immunotherapy for Renal Cell Carcinoma
Clin. Cancer Res.,
September 15, 2004;
10(18):
6353S - 6359S.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. J. DeAngelo, E. P. Hochberg, E. P. Alyea, J. Longtine, S. Lee, I. Galinsky, B. Parekkedon, J. Ritz, J. H. Antin, R. M. Stone, et al.
Extended Follow-up of Patients Treated with Imatinib Mesylate (Gleevec) for Chronic Myelogenous Leukemia Relapse after Allogeneic Transplantation: Durable Cytogenetic Remission and Conversion to Complete Donor Chimerism without Graft-versus-Host Disease
Clin. Cancer Res.,
August 1, 2004;
10(15):
5065 - 5071.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Bader, H. Kreyenberg, W. Hoelle, G. Dueckers, R. Handgretinger, P. Lang, B. Kremens, D. Dilloo, K.-W. Sykora, M. Schrappe, et al.
Increasing Mixed Chimerism Is an Important Prognostic Factor for Unfavorable Outcome in Children With Acute Lymphoblastic Leukemia After Allogeneic Stem-Cell Transplantation: Possible Role For Pre-Emptive Immunotherapy?
J. Clin. Oncol.,
May 1, 2004;
22(9):
1696 - 1705.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. H.M. Heemskerk, M. Hoogeboom, R. Hagedoorn, M. G.D. Kester, R. Willemze, and J.H. F. Falkenburg
Reprogramming of Virus-specific T Cells into Leukemia-reactive T Cells Using T Cell Receptor Gene Transfer
J. Exp. Med.,
April 5, 2004;
199(7):
885 - 894.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. W. Childs
Evolving trends in hematopoietic cell transplantation for solid tumors: tempering enthusiasm with clinical reality
Ann. Onc.,
April 1, 2004;
15(4):
543 - 544.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Y. Mapara and M. Sykes
Tolerance and Cancer: Mechanisms of Tumor Evasion and Strategies for Breaking Tolerance
J. Clin. Oncol.,
March 15, 2004;
22(6):
1136 - 1151.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. S. Peggs, K. Thomson, D. P. Hart, J. Geary, E. C. Morris, K. Yong, A. H. Goldstone, D. C. Linch, and S. Mackinnon
Dose-escalated donor lymphocyte infusions following reduced intensity transplantation: toxicity, chimerism, and disease responses
Blood,
February 15, 2004;
103(4):
1548 - 1556.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H.-J. Kolb, C. Schmid, A. J. Barrett, and D. J. Schendel
Graft-versus-leukemia reactions in allogeneic chimeras
Blood,
February 1, 2004;
103(3):
767 - 776.
[Abstract]
[Full Text]
[PDF]
| |
